AbbVie reports Phase 3 success for lutikizumab in painful skin disease, eyes FDA filing next year

AbbVie announced positive Phase 3 trial results for its experimental IL-1α and IL-1β inhibitor lutikizumab, which is being developed to treat a debilitating skin condition.

The study reported improved patient responses, suggesting the drug's efficacy in reducing disease symptoms.

Following the successful readout, the company indicated that it expects to file an FDA application for the therapy sometime next year.

Analysts view the result as a favorable development for AbbVie's dermatology pipeline and could bolster its future market prospects.